Sensible Care program of the Dutch Healthcare Institute replaced by Appropriate Care program

12

Nov 2021

In 2013, the Dutch Healthcare Institute (ZIN) launched the Sensible Care program (Zinnige Zorg) for a systematic review of the diagnostic and treatment options within the current basic health insurance package to provide appropriate provision and use of medical care. The program is typically related to certain disease/disease groups and consists of four phases:

  • Screening phase: the ZIN examines with the parties involved which care is currently being provided and which subjects can be improved;
  • In-depth phase: ZIN determines for each topic what can be improved and discuss with the parties involved how they will achieve this;
  • Implementation phase: the parties implement the improvements. The ZIN supports them where necessary;
  • Evaluation phase: the final stage when ZIN checks whether the goals have been achieved.

At the request of the Minister for Medical Care, the ZIN and the Dutch Healthcare Authority (NZa) issued advice "Working together on appropriate care: the future is now" at the end of 2020. In this advice, the four basic principles for the Appropriate Care program are listed:

  • Appropriate Care is value-driven (gain in health and quality of life for patients at a reasonable price);
  • Appropriate Care is established together with the patient (joint decision on the most appropriate treatment);
  • Appropriate Care means the right care in the right place (closer where possible, further away if necessary, e-health);
  • Appropriate Care is not about illness but about health (looking at what someone can still do and prevention).

The ongoing 29 projects under the Sensible Care program will continue in the context of Appropriate Care.

The full details in Dutch can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

25

Mar 2022

On March 4, 2022, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced three projects which received a subsidy under the "Subsidy scheme for promising care" in 2022 for research of a new minimally invasive endoscopy-guided surgery in patients with spontaneous cerebral hemorrhage, oral immunotherapy in children to cure a food allergy and cutting the diaphragm band in chronic abdominal complaints.

Read more

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more